Life Science Analytics Market Projected to Reach $64.51 Billion by 2030 Amid Accelerating AI Integration
Yahoo Finance ·
According to ResearchAndMarkets, the worldwide life science analytics sector is expanding rapidly, transitioning from $31.24 billion in 2025 to $36.07 billion in 2026 with a 15.5% compound annual growth rate. The industry is forecasted to hit $64.51 billion by 2030, maintaining a 15.6% CAGR as artificial intelligence adoption surges. Key players such as Oracle, IBM, and Microsoft are driving this momentum by integrating AI-powered capabilities into drug discovery, clinical trials, and regulatory compliance. Moreover, rising chronic disease prevalence, precision medicine initiatives, and the demand for evidence-based healthcare continue to bolster digital infrastructure investments across pharmaceutical and biotech organizations globally.
AI 시장 분석
The global life sciences analytics market is projected to grow at a CAGR of 15.6% from $36.07 billion in 2026 to $64.51 billion in 2030. Accelerated AI adoption by major tech companies like Oracle, Microsoft, and IBM, alongside demand for precision medicine, is driving this growth. Investors should focus on the expansion of healthcare digital infrastructure and the profitability improvement of data-driven solution companies.
상승 영향
- AI — Accelerated AI adoption by major companies like Oracle, IBM, and Microsoft directly increases sales and profitability of AI solutions in the life sciences sector.
- Biotechnology — The life sciences analytics market is growing to $64.51 billion by 2030 with a CAGR of 15.6%, significantly improving drug discovery and clinical efficiency.
DYAX 전담 분석
The 15.6% CAGR growth in the life sciences analytics market is a direct reflection of pharmaceutical and biotech companies' demand for AI-driven drug discovery and clinical trial efficiency. Platform advancements by major tech companies are leading to expanded sales in related software and cloud sectors.
The bullish scenario involves corporate earnings exceeding expectations due to a surge in demand for precision medicine and chronic disease management data, while the bearish scenario entails increased adoption costs driven by tighter regulations. Key monitoring indicators are clinical data platform adoption rates and the scale of AI-related R&D investments.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 53% · Bearish (Short) 47%
280 participants
Related News
- Meta Critical Minerals Welcomes West Point Senior Advisor John Melkon to Advisory Board
- Conga Expands AI Across Commerce Lifecycle with MCP Server and AiMe
- One Software Stock to Watch and Two to Reconsider
- Global Data Center Air Handling Units Market Forecast to 2032
- Dow Futures Climb While Nasdaq Stays Flat Ahead of Inflation Data and Major Earnings
- NextEra Energy's 31-Year Dividend Streak: The Key Metric to Review Before Investing
